BoTox can help with bladder problems

Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, Sievert KD, Brin MF, Jenkins B, Thompson C, Lam W, Heesakkers J, Haag-Molkenteller C. OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Aetiology. Adv Ther. 2013 [Epub ahead of print]

INTRODUCTION: To evaluate the efficacy and safety of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity (NDO) in subpopulations of etiology (multiple sclerosis [MS] or spinal cord injury [SCI]) and concomitant anticholinergics (use/non-use).
METHODS: Data were pooled from two double-blind, placebo-controlled, pivotal, phase 3 studies including a total of 691 patients with ≥14 urinary incontinence (UI) episodes/week due to MS (n = 381) or SCI (n = 310). Patients received intradetrusor injections of onabotulinumtoxinA 200U (n = 227), 300U (n = 223), or placebo (n = 241). Change from baseline at week 6 in UI episodes/week (primary endpoint), urodynamics, quality of life (QOL), and adverse events (AEs) were assessed.
RESULTS: Significant and similar reductions in UI episodes were observed regardless of aetiology or anti-cholinergic use: at week 6, mean weekly decreases of -22.6 and -19.6 were seen in MS and SCI patients, respectively, and -20.3 and -22.5 in anticholinergic users and non-users, respectively, treated with onabotulinumtoxinA 200U. The 300U dose did not add to the clinical efficacy in any subpopulation. Similar proportions of patients achieved ≥50% or 100% reductions in UI episodes in all subgroups. Improvements in maximum cystometric capacity, maximum detrusor pressure during first involuntary detrusor contraction, and QOL were significant in both etiologies and were independent of anticholinergic use. The most common AEs in all groups were urinary tract infection and urinary retention.
CONCLUSION: Regardless of concomitant anticholinergic use or aetiology, onabotulinumtoxinA significantly improved UI symptoms, urodynamics, and QOL in patients with UI due to NDO. OnabotulinumtoxinA was well tolerated in all groups.


This is yet another report suggesting the usefulness of botox treatment for bladder problems. If you are having problems speak to your MS Nurse Neurologists Urologist. 

Please ignore any adverts from bots that occur follow any mention of Botox 

COI None.

11 Dec 2012
Gaillet et al. Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity. Prog Urol. 2012;22:1064-70. doi: 10.1016/j.purol.2012.10.006. INTRODUCTION: The ...
09 Jul 2012
METHODS: Twenty-three patients with MS contributed data from 33 upper limbs to this study. Each limb was randomized in a crossover design to receive botulinum toxin type A or placebo at baseline and the reverse treatment ...
25 Nov 2011
Purpose: Neurogenic detrusor overactivity (NDO. The muscle controlling bladder contraction is over active = urinary incontinence) is common in patients who suffer from multiple sclerosis (MS). When the usual ...
18 Apr 2012
PURPOSE: We assessed the efficacy, safety and effects on quality of life of onabotulinumtoxinA in patients with neurogenic detrusor overactivity. MATERIALS AND METHODS: In this 52-week, international, multicenter, ...

13 Sep 2012
AIMS: OnabotulinumtoxinA significantly reduces urinary incontinence (UI) and improves bladder management in patients with neurogenic detrusor overactivity (NDO). We evaluated the impact of onabotulinumtoxinA on ...
11 Nov 2012
METHODS: Between January 2003 and March 2011, 11 patients (aged 23-75 years) were treated with 40 injections of botulinum toxin type A 300 U. The patients were followed up for 4, 8 and 12 weeks after treatment.
01 Aug 2011
Objective:To assess the effects of onabotulinumtoxinA (BOTOX(®), Allergan, Inc.) on urinary incontinence in people with detrusor bladder problems. Trial: This multicentre, randomised, double-blind, placebo-controlled study ...
02 Mar 2012
Most MS'ers would be offered Botox in combination with intermittent self-catheterisation, when medication is not helpful. But for people who are not candidates for Botox, a new treatment is good news. Talk to your doctor and ...


Labels: ,